Imjudo(tremelimumab)
Imjudo, Tremelimumab (tremelimumab) is an antibody pharmaceutical. Tremelimumab was first approved as Imjudo on 2022-10-21. It is used to treat hepatocellular carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma and non-small-cell lung carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Imjudo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tremelimumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Imjudo | tremelimumab-actl | AstraZeneca | N-761289 RX | 2022-10-21 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imjudo | Biologic Licensing Application | 2024-07-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatocellular carcinoma | — | D006528 | C22.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
tremelimumab, Imjudo, AstraZeneca AB | |||
| 2029-10-21 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1116 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 137 | 188 | 30 | 2 | 48 | 351 |
| Neoplasms | D009369 | — | C80 | 103 | 89 | 6 | 1 | 10 | 165 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 41 | 62 | 22 | 1 | 8 | 116 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 30 | 44 | 8 | 1 | 15 | 91 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 8 | 15 | 4 | 1 | 9 | 33 |
| Oncogenes | D009857 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 80 | 121 | 20 | — | 17 | 210 |
| Non-small-cell lung carcinoma | D002289 | — | — | 42 | 67 | 23 | — | 13 | 124 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 31 | 32 | 4 | — | 4 | 60 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 16 | 36 | 9 | — | 4 | 55 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 16 | 35 | 10 | — | 1 | 51 |
| Prostatic neoplasms | D011471 | — | C61 | 20 | 34 | 3 | — | — | 50 |
| Colorectal neoplasms | D015179 | — | — | 23 | 31 | 4 | — | 1 | 48 |
| Adenocarcinoma | D000230 | — | — | 15 | 33 | 2 | — | 2 | 46 |
| Recurrence | D012008 | — | — | 24 | 23 | 2 | — | — | 43 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 23 | 25 | 1 | — | 2 | 43 |
Show 31 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 28 | 12 | — | — | — | 31 |
| Leukemia | D007938 | — | C95 | 15 | 4 | — | — | — | 18 |
| Transitional cell carcinoma | D002295 | — | — | 11 | 12 | — | — | — | 17 |
| Urologic neoplasms | D014571 | — | C64-C68 | 12 | 9 | — | — | 1 | 16 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 9 | 11 | — | — | — | 16 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 11 | 6 | — | — | — | 14 |
| Triple negative breast neoplasms | D064726 | — | — | 8 | 9 | — | — | — | 14 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 3 | 12 | — | — | — | 14 |
| Myelodysplastic syndromes | D009190 | — | D46 | 11 | 2 | — | — | — | 13 |
| Multiple myeloma | D009101 | — | C90.0 | 9 | 6 | — | — | — | 12 |
Show 179 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 5 | — | — | — | — | 5 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 5 | — | — | — | — | 5 |
| Lymphoid leukemia | D007945 | — | C91 | 4 | — | — | — | — | 4 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 3 | — | — | — | — | 3 |
| Mycoses | D009181 | — | B35-B49 | 3 | — | — | — | — | 3 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 3 | — | — | — | — | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | 3 | — | — | — | — | 3 |
| Mycosis fungoides | D009182 | — | C84.0 | 3 | — | — | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 2 | — | — | — | — | 2 |
Show 34 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | — | — | — | — | 4 | 4 |
| Myocarditis | D009205 | — | I51.4 | — | — | — | — | 3 | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 3 | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Microbiota | D064307 | — | — | — | — | — | — | 2 | 2 |
| Metagenome | D054892 | — | — | — | — | — | — | 2 | 2 |
| Multiple primary neoplasms | D009378 | — | — | — | — | — | — | 2 | 2 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
| Pericarditis | D010493 | EFO_0007427 | I30 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tremelimumab |
| INN | tremelimumab |
| Description | Tremelimumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5GGV:H|heavy chain
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLY
LQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH
>5GGV:L|light chain
DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 5GGU, 5GGV |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108658 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11771 |
| UNII ID | QEN1X95CIX (ChemIDplus, GSRS) |
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Imjudo – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,319 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,737 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use